ArticlePloS one2025
Advance directives prior to COVID-19 diagnosis in a United States national healthcare system.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn advance directive (AD) document allows a patient to indicate their health care preferences and identify an agent to make decisions on their behalf if they lose their ability to communicate. Due to the substantially elevated risk of acute respiratory failure and death during the COVID-19 pandemic, ADs were especially relevant. The objective of this study was to describe AD completed prior to COVID-19 infection (COVID-19) among patients receiving care in a national healthcare system.
methodsWe conducted a cohort study of United States Veterans Health Administration (VA) patients with COVID-19 between March 2020 and December 2022. AD completion before COVID-19 was ascertained by progress note titles in the electronic health record. Covariates included age, sex, race/ethnicity, marital status, geographic region, health care utilization, calendar quarter of COVID-19, and VA COVID-19 (VACO) 30-day mortality index score.
resultsAmong 422,028 COVID-19 patients (median age = 62 years; 88.5% male; 58.6% non-Hispanic White (NH-White), 23.3% non-Hispanic Black (NH-Black), 9.2% Hispanic), 67,970 (16.1%) had AD documentation which varied substantially across all covariates. AD completion increased with VACO Index quintiles ranging from 8.2 to 31.0%. In a model adjusted for covariates, relative to NH-White, NH-Black and Hispanic groups had decreased odds for AD (NH-Black odds ratio (OR)=0.77 (95% confidence interval 0.76-0.79); Hispanic OR=0.85 (0.82-0.87)). VACO index includes age, and both were strongly associated with AD completion. Women compared to men, and those who were widowed, separated/divorced and never married relative to people who were married, had increased AD completion.
conclusionsAD completion was overall low, including among patients at high risk of mortality due to COVID-19. When controlling for age, risk for mortality and other covariates, men and people who identify as Black or Hispanic were less likely to have completed an AD. Investment in interventions to facilitate AD completion are needed, particularly among historically underrepresented populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.